Why does semaglutide cause heartburn?

The likely reason is slower stomach emptying. In a 30-person trial, the stomach emptied about 27% less in the first hour after a meal on semaglutide than on placebo. Food that lingers keeps the stomach fuller for longer, which gives acid more chances to push back up into the food pipe. That is the best-supported explanation, though no study has traced it step by step.

How long does heartburn from semaglutide last?

There is no measured reflux timeline. The Wegovy label says reflux and indigestion were reported most often during dose escalation, and pooled STEP trial data show stomach side effects were mostly temporary and clustered around dose increases. Those trials tracked nausea, diarrhea, vomiting and constipation over time, not reflux itself. Heartburn that continues at a steady dose is worth raising with the prescriber.

What helps acid reflux on semaglutide?

Doctors commonly start with the standard reflux measures: the American College of Gastroenterology suggests avoiding meals within two to three hours of bedtime, raising the head of the bed for nighttime symptoms and cutting back on personal trigger foods. A 2025 Mayo Clinic Proceedings review adds smaller, more frequent meals and fewer high-fat foods for GLP-1 stomach effects. Medicines and any dose change belong with the prescriber.

When is heartburn on semaglutide a warning sign?

Chest pain, trouble or pain swallowing, persistent vomiting, vomit that contains blood or looks like coffee grounds, and black, tarry stools all call for prompt medical care. Chest pain can come from the heart, so it should never be assumed to be reflux. Persistent or severe belly pain, sometimes spreading to the back, can be a sign of pancreatitis and needs urgent assessment.

Does tirzepatide cause less acid reflux than semaglutide?

There is no fair head-to-head answer from the labels. The Zepbound label lists reflux disease in 4% to 5% of adults versus 2% on placebo, and indigestion in 9% to 10% versus 4%. Those come from separate trials with different designs, so the numbers can't be ranked against semaglutide's. Whether switching makes sense is a decision for the prescriber, weighing more than reflux alone.

Does Semaglutide Cause Acid Reflux? Sometimes

Does semaglutide cause acid reflux? For some people, yes. Heartburn, indigestion and reflux are listed side effects of semaglutide, and in trials they turned up more often than on placebo. They are much less common than nausea. In the weight-loss trials behind Wegovy, about 5 in 100 adults on semaglutide were recorded with reflux disease, against 3 in 100 on placebo. Symptoms tend to arrive in the weeks after starting or raising the dose, and most are mild. A few specific signs, covered below, mean it is time to call a doctor rather than wait.

Does semaglutide cause acid reflux? The Wegovy and Ozempic numbers

The cleanest figures come from each brand's official label. Two terms first: GERD (gastroesophageal reflux disease) is reflux frequent or bothersome enough to count as a condition. Dyspepsia is the medical word for indigestion: burning, fullness or discomfort in the upper belly.

Label and trial group	Symptom	Semaglutide	Placebo
Wegovy 2.4 mg, adults in weight-loss trials	Indigestion (dyspepsia)	9%	3%
Wegovy 2.4 mg	Reflux disease (GERD)	5%	3%
Wegovy 2.4 mg	Gastritis (irritated stomach lining)	4%	1%
Ozempic 0.5 mg / 1 mg, adults with type 2 diabetes	Indigestion (dyspepsia)	3.5% / 2.7%	1.9%
Ozempic 0.5 mg / 1 mg	Reflux disease (GERD)	1.9% / 1.5%	0%

The Wegovy rows come from the current Wegovy label on DailyMed (Revised: 6/2026), which pooled 2,116 adults on semaglutide and 1,261 on placebo; its Medication Guide lists heartburn among the most common side effects. The Ozempic rows come from the current Ozempic label on DailyMed (Revised: 5/2026), from lower doses in a different group of people, so the two aren't a head-to-head comparison.

Belching sits in the same family, at 7% versus under 1% with Wegovy, and has its own page on semaglutide sulfur burps. The full list lives in semaglutide side effects.

Why semaglutide heartburn happens

The likely reason is that semaglutide slows how fast the stomach empties. In a small trial, 30 adults with obesity spent 12 weeks on semaglutide and 12 on placebo. In the first hour after a test meal, the stomach emptied about 27% less on semaglutide, though over five hours the difference wasn't statistically significant (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018). The meal isn't stuck. It just lingers longer early on.

A fuller stomach for longer gives acid more chances to push back past the lower esophageal sphincter, the ring of muscle at the bottom of the food pipe that normally keeps it down. Delayed emptying is a known risk factor for GERD, which is why researchers see it as the most likely link, though it remains an explanation rather than a proven cause.

There is a pull the other way: the American College of Gastroenterology's GERD guideline strongly recommends weight loss for overweight people with reflux (Katz et al., American Journal of Gastroenterology, 2022). Even so, the larger studies below found reflux diagnoses ticking up slightly on these drugs.

What the larger studies add

Labels count symptoms from the trials behind each brand. Bigger analyses asked how many extra cases of reflux disease GLP-1 drugs, the class semaglutide belongs to, actually account for.

A 2025 review of 55 placebo-controlled trials with 106,395 participants found the drugs probably raised the risk of GERD by roughly 4 extra cases per 1,000 people (Chiang et al., Gastroenterology, 2025).
A 2025 UK study compared 24,708 adults with type 2 diabetes starting a GLP-1 drug against 89,096 starting an SGLT-2 inhibitor, a different diabetes medicine. Over about three years, the GLP-1 group was diagnosed with GERD 27% more often, about 7 extra diagnoses per 1,000 people (Noh et al., Annals of Internal Medicine, 2025).

As of September 22, 2026, the day this article was written, a new paper pointed the same way. A September 2, 2026 analysis of side-effect reporting systems in the U.S., Japan and Canada found reflux made up about two to five times as large a share of side-effect reports for GLP-1 drugs as for DPP-4 inhibitors, another diabetes class, with semaglutide showing the strongest signal (Choi et al., Gut and Liver, 2026). Reporting systems count reports, not patients, so they flag a pattern without measuring how often it happens.

Put together: heartburn and indigestion are fairly common on semaglutide, while the extra reflux disease linked to the drug comes to a few people per thousand.

When reflux tends to show up

The Wegovy label says indigestion, reflux, belching and gastritis were "most frequently reported during dosage escalation," the step-by-step dose increases of the first months. A pooled analysis of the STEP 1–3 weight-loss trials found stomach side effects in general were mostly mild to moderate, temporary, and bunched up during or shortly after a dose increase (Wharton et al., Diabetes, Obesity and Metabolism, 2022).

That analysis tracked nausea, diarrhea, vomiting and constipation over time, not reflux, so there is no measured date when heartburn should fade. The nausea timeline is in how long GLP-1 nausea lasts. Heartburn that keeps going at a steady dose is worth raising with the prescriber.

What doctors commonly suggest for heartburn on a GLP-1

The standard reflux advice suits a slower stomach. The ACG guideline suggests avoiding meals within two to three hours of bedtime, raising the head of the bed for nighttime symptoms, avoiding tobacco and cutting back on personal trigger foods. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) names common trigger foods, among them citrus, tomatoes, alcohol, coffee, high-fat food and spicy food (NIDDK). For GLP-1 stomach side effects generally, a 2025 review for primary-care doctors puts smaller, more frequent meals, enough fluids and fewer high-fat or high-sugar foods first (Saha et al., Mayo Clinic Proceedings, 2025).

Reflux medicines are a conversation for the prescriber or pharmacist. One label detail matters for the pill form: Wegovy tablets are taken on an empty stomach with a little water, and the label calls for at least 30 minutes before any food, drink or other oral medicine, so the timing of an antacid is worth settling with a pharmacist. If heartburn arrives with a dose increase, a prescriber may choose to hold the current dose longer.

Would switching to tirzepatide help?

Not reliably. Tirzepatide also acts on the GLP-1 receptor, and its Zepbound label on DailyMed (Revised: 8/2026) lists reflux disease in 4% to 5% of adults across doses versus 2% on placebo, and indigestion in 9% to 10% versus 4%. The 2026 reporting analysis found a reflux signal for tirzepatide too. Separate trials can't be lined up as a fair contest, and a switch is the prescriber's decision, based on more than reflux alone.

When reflux needs prompt medical attention

NIDDK lists symptoms that call for a doctor rather than another antacid: chest pain, persistent vomiting, trouble or pain swallowing, and signs of bleeding, such as vomit that contains blood or looks like coffee grounds, or black, tarry stools (NIDDK). Its list also includes loss of appetite and weight loss, which are harder to read on a medicine that lowers appetite on purpose. Chest pain can come from the heart as well as the esophagus, and only an exam can tell them apart.

The Wegovy label adds its own: severe stomach side effects were reported in 4.1% of adults on the injection versus 0.9% on placebo, and persistent or severe belly pain, sometimes spreading to the back, is how it describes possible pancreatitis. A slow stomach also matters under sedation, which semaglutide before surgery covers.

Semaglutide through Promise

Those label numbers come from trials of the branded products. Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation where they judge it appropriate, and that decision is between you and your doctor.

Existing reflux, a hiatal hernia, gastroparesis (a stomach that already empties very slowly) and current medicines are all part of what the reviewing provider weighs. A licensed provider reviews every request, and not everyone qualifies. If heartburn shows up after a dose change, that same relationship is where it gets reported and the next dose decided.